A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

CAPS and NLRP3

(2019) Laela M. Booshehri et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy

(2019) Daniele Lecis et al.   Cancers

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization

(2018) Fei Zhao et al.   IMMUNITY

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

(2018) Jinyang Li et al.   IMMUNITY

Gain of function mutation and inflammasome driven diseases in human and mouse models

(2018) Mario D. Cordero et al.   JOURNAL OF AUTOIMMUNITY

CXCL5 Facilitates Melanoma Cell–Neutrophil Interaction and Lymph Node Metastasis

(2018) Ana Soler-Cardona et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

(2018) Natalie J. Neubert et al.   Science Translational Medicine

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade

(2018) Limo Chen et al.   Cancer Discovery

Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF-β Inhibitor Sequencing in Melanoma

(2018) Fei Zhao et al.   Cancer Immunology Research

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion

(2018) Peixin Dong et al.   Frontiers in Oncology

Role of the NLRP3 inflammasome in cancer

(2018) Maryam Moossavi et al.   Molecular Cancer

Blocking ATP-sensitive potassium channel alleviates morphine tolerance by inhibiting HSP70-TLR4-NLRP3-mediated neuroinflammation

(2017) Jie Qu et al.   Journal of Neuroinflammation

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

(2017) Maria Gato-Cañas et al.   Cell Reports

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

(2016) Colin W. Steele et al.   CANCER CELL

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

The human HSP70 family of chaperones: where do we stand?

(2016) Jürgen Radons   CELL STRESS & CHAPERONES

Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

(2016) M. Sade-Feldman et al.   CLINICAL CANCER RESEARCH

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Mechanism and Regulation of NLRP3 Inflammasome Activation

(2016) Yuan He et al.   TRENDS IN BIOCHEMICAL SCIENCES

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma

(2016) T. Chao et al.   Cancer Immunology Research

Alternative Wnt Signaling Activates YAP/TAZ

(2015) Hyun Woo Park et al.   CELL

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

(2015) Rebecca C Coll et al.   NATURE MEDICINE

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

(2015) G. Wang et al.   Cancer Discovery

Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

(2015) A. Holtzhausen et al.   Cancer Immunology Research

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

The HSP70 family and cancer

(2013) M. E. Murphy   CARCINOGENESIS

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Cytoplasmic STAT3 Represses Autophagy by Inhibiting PKR Activity

(2012) Shensi Shen et al.   MOLECULAR CELL

Novel role of PKR in inflammasome activation and HMGB1 release

(2012) Ben Lu et al.   NATURE

Selective enrichment of newly synthesized proteins for quantitative secretome analysis

(2012) Katrin Eichelbaum et al.   NATURE BIOTECHNOLOGY

Toll-Like Receptor 4 Activation in Cancer Progression and Therapy

(2011) Alja Oblak et al.   Clinical & Developmental Immunology

Toll-like Receptor 4 (TLR4) Is Essential for Hsp70-like Protein 1 (HSP70L1) to Activate Dendritic Cells and Induce Th1 Response

(2011) Hongliang Fang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells

(2010) H. W. van Deventer et al.   CANCER RESEARCH

Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice

(2008) Shuiping Tu et al.   CANCER CELL

WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome

(2008) P. D. Da Forno et al.   CLINICAL CANCER RESEARCH

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells

(2008) Ilaria Marigo et al.   IMMUNOLOGICAL REVIEWS